Cyanine Dye Conjugation Enhances Crizotinib Localization to Intracranial Tumors, Attenuating NF-κB-Inducing Kinase...

Area of Science:

• Oncology
• Pharmacology
• Nanomedicine

Background:

• Glioblastoma (GBM) is an aggressive brain cancer with poor outcomes.
• Current treatments for GBM are limited, partly due to poor drug penetration of the blood-brain barrier.
• Crizotinib shows preclinical promise but faces delivery challenges.

Purpose of the Study:

• To identify novel therapeutic strategies for glioblastoma.
• To investigate Crizotinib as an inhibitor of nuclear factor-κB (NF-κB)-inducing kinase (NIK) in GBM.
• To evaluate the efficacy of a near-infrared dye-conjugated Crizotinib (IR-Crizotinib) for improved GBM treatment.

Main Methods:

• Identified Crizotinib as a novel inhibitor of NIK, a key regulator of GBM.
• Conjugated Crizotinib to a near-infrared dye to create IR-Crizotinib.
• Assessed the efficacy of IR-Crizotinib in vitro and in orthotopic mouse xenograft GBM models.

Main Results:

• IR-Crizotinib significantly attenuated glioma cell proliferation and survival in vitro compared to unconjugated Crizotinib.
• Enhanced IR-Crizotinib localization to GBM tumors in vivo was observed.
• IR-Crizotinib demonstrated improved intracranial delivery, tumor targeting, and inhibition of NIK/NF-κB signaling.

Conclusions:

• IR-Crizotinib represents a promising therapeutic agent for glioblastoma.
• The conjugate overcomes blood-brain barrier limitations, enhancing chemotherapeutic delivery and efficacy.
• IR-Crizotinib reduces glioma growth and increases survival in preclinical models.